Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis

Mortality rates of coronavirus disease-2019 (COVID-19) continue to rise across the world. Information regarding the predictors of mortality in patients with COVID-19 remains scarce. Herein, we performed a systematic review of published articles, from 1 January to 24 April 2020, to evaluate the risk factors associated with mortality in COVID-19. Two investigators independently searched the articles and collected the data, in accordance with PRISMA guidelines. We looked for associations between mortality and patient characteristics, comorbidities, and laboratory abnormalities. A total of 14 studies documenting the outcomes of 4659 patients were included. The presence of comorbidities such as hypertension (odds ratio [OR], 2.5; 95% confidence interval [CI], 2.1-3.1;P < .00001), coronary heart disease (OR, 3.8; 95% CI, 2.1-6.9;P < .00001), and diabetes (OR, 2.0; 95% CI, 1.7-2.3;P < .00001) were associated with significantly higher risk of death amongst patients with COVID-19. Those who died, compared with those who survived, differed on multiple biomarkers on admission including elevated levels of cardiac troponin (+44.2 ng/L, 95% CI, 19.0-69.4;P = .0006); C-reactive protein (+66.3 mu g/mL, 95% CI, 46.7-85.9;P < .00001); interleukin-6 (+4.6 ng/mL, 95% CI, 3.6-5.6;P < .00001); D-dimer (+4.6 mu g/mL, 95% CI, 2.8-6.4;P < .00001); creatinine (+15.3 mu mol/L, 95% CI, 6.2-24.3;P = .001); and alanine transaminase (+5.7 U/L, 95% CI, 2.6-8.8;P = .0003); as well as decreased levels of albumin (-3.7 g/L, 95% CI, -5.3 to -2.1;P < .00001). Individuals with underlying cardiometabolic disease and that present with evidence for acute inflammation and end-organ damage are at higher risk of mortality due to COVID-19 infection and should be managed with greater intensity.